Filing Flows › Kymera Therapeutics (KYMR) › Q2 2025
Kymera Therapeutics (KYMR) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Kymera Therapeutics (KYMR) reported revenue of $11.5M for the second quarter 2025 (Q2 2025), -55% from a year earlier and -48% from the quarter before. Operating margin was -736.8%, net loss $76.6M (667.6% of revenue).
Kymera Therapeutics, Q2 2025: revenue $11.5M (-55% year over year), operating margin -736.8%, net loss $76.6M, operating cash flow −$59.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.5M | -48% | -55% |
| Operating profit | −$84.6M | — | — |
| Net earnings | −$76.6M | — | — |
| Operating cash flow | −$59.9M | — | — |
What changed
Revenue was $11.5M in Q2 2025, down 55% year over year and down 48% from the previous quarter.
Operating costs exceeded revenue by $84.6M, an operating margin of -736.8%. Total costs grew 25% against a revenue fall of 55%. The quarter ended with a net loss of $76.6M, wider than the previous quarter's $65.6M loss.
Operating cash flow was −$59.9M. Non-cash charges added back $2.1M of depreciation and amortization and $15.4M of share-based compensation. Capital expenditures of $695K exceeded it, leaving free cash flow of −$60.6M.
Questions
What was Kymera Therapeutics' revenue in the second quarter 2025?
Kymera Therapeutics (KYMR) reported revenue of $11.5M for the second quarter 2025 (Q2 2025), -55% from a year earlier and -48% from the quarter before.
Was Kymera Therapeutics profitable in the second quarter 2025?
Operating loss was $84.6M (-736.8% of revenue) and net loss $76.6M.